Hornykiewicz O, Kish S J
Can J Neurol Sci. 1984 Feb;11(1 Suppl):185-90. doi: 10.1017/s0317167100046382.
According to their mental status, patients with Parkinson's disease can be subdivided into three groups: (1) mentally normal patients; (2) patients with severe cognitive impairment and Alzheimer-type brain pathology (neuritic plaques, neurofibrillary tangles, granulovacuolar changes); and (3) demented patients without any evidence of Alzheimer changes. Neurochemically, irrespective of the presence or absence of Alzheimer-type brain pathology, demented Parkinson patients seem to have the same disturbance of cortical cholinergic neuron function as patients with Alzheimer-type dementia (Alzheimer's disease), namely, reduced levels of cortical acetylcholine esterase and choline acetyltransferase activity. At present, the question whether the "cortical cholinergic deficiency" is the only (or sufficient) neurochemical basis for the cognitive impairment in Parkinson patients with dementia cannot be answered with certainty; the additional role of other neurotransmitter changes known to occur in the Parkinson brain, especially loss of cortical, hippocampal and subcortical noradrenaline and/or dopamine cannot be ruled out.
根据精神状态,帕金森病患者可分为三组:(1)精神正常的患者;(2)有严重认知障碍且伴有阿尔茨海默型脑病理改变(神经炎性斑块、神经原纤维缠结、颗粒空泡变性)的患者;(3)无任何阿尔茨海默改变证据的痴呆患者。从神经化学角度来看,无论是否存在阿尔茨海默型脑病理改变,帕金森病痴呆患者似乎与阿尔茨海默型痴呆(阿尔茨海默病)患者具有相同的皮质胆碱能神经元功能紊乱,即皮质乙酰胆碱酯酶水平降低和胆碱乙酰转移酶活性降低。目前,“皮质胆碱能缺乏”是否是帕金森病痴呆患者认知障碍的唯一(或充分)神经化学基础这一问题尚无法确定回答;帕金森病脑中已知发生的其他神经递质变化的额外作用,尤其是皮质、海马和皮质下去甲肾上腺素和/或多巴胺的丧失,不能排除在外。